Comprehensive Assessment of COVID-19 Vaccine Efficacy, Immunogenicity, and Safety: A Systematic Review

Hadi Shnar Jabr Lsloom[1], Omar Mohammed Bidah Alnawfal[2], Samirah Hamadi Mohammed Maashi[3], Fatemah Abdullah Abdulaziz Alhubaishi[4], Reham Ali Mohammed Aljurayad[5], Nahar Munyif M Alshahrani[6], Nawaf Mansour Saeed Alqahtani[7]

[1]Medical laboratory specialist, Armed Forces Hospital, Najran
[2]Specialist-Public Health, Military Industries Corporation Hospital, Al Kharj
[3]Specialist-Nursing, Military Industries Corporation Hospital, Al Kharj
[4]Specialist-psychology, Military Industries Corporation Hospital, Al Kharj
[5]Health Assistant, Military Industries Corporation Hospital, Al Kharj
[6]Technician-Emergency Medical Services, Armed Forces Hospital, Najran
[7]Specialist-Medical Devices, MoD Health Services, Riyadh, Saudi Arabia

ABSTRACT

Following the World Health Organization's (WHO) announcement of the Coronavirus Disease 2019 (COVID-19) pandemic in January 2020, the want for ongoing monitoring has been emphasized because of sudden traits associated with Coronavirus Disease 2019 (COVID-19) vaccination. This research explores a systematic synthesis of studies to evaluate the lasting effectiveness, immune response, and protection of Coronavirus Disease 2019 (COVID-19) vaccines. Additionally, the evaluation consists of the crucial consideration of tackling new variants.

Methodology: This research constitutes an umbrella review focusing on the viability and efficacy of Coronavirus Disease 2019 (COVID-19) vaccines.A thorough investigation was conducted across PubMed, Web of Science, and Scopus databases, utilizing keywords associated with Coronavirus Disease 2019 (COVID-19) vaccination. Inclusion criteria centered on peer-reviewed systematic reviews and meta-analyses in English, explicitly emphasizing feasibility and efficacy. Exclusion parameters targeted non-systematic reviews solely concerning vaccine safety and eliminated duplicates. Data synthesis encompassed narrative and potentially quantitative synthesis through metaanalysis, adhering to PRISMA guidelines.

Results: The study encompassed 23 systematic reviews. Findings suggested that Coronavirus Disease 2019 (COVID-19) vaccines generally exhibit both safety and efficacy across a spectrum of medical conditions. The overall bias risk for the included studies was deemed low.

Conclusions: The examine's effects indicated that mRNA vaccines present a better incidence of unfavourable events however demonstrate superior efficacy. Conversely, inactivated and better protection profiles signify protein subunit vaccines however show off reduced effectiveness. Furthermore, the vaccine became deemed secure for individuals with particular conditions which include inflammatory bowel disorder, stable organ transplant recipients, children, pregnant individuals, and those with hematologic disorders. Ultimately, man or woman attractiveness of the Coronavirus Disease 2019 (COVID-19) vaccine is motivated by using many elements, consisting of geographical, socioeconomic, and pandemic-related issues.

Keywords: Coronavirus Disease 2019 (COVID-19), SARS-CoV-2, Vaccines, Feasibility, Effectiveness

INTRODUCTION

The international health disaster initiated via the Coronavirus Disease 2019 (COVID-19) pandemic has brought unparalleled complexities to the healthcare.

The rapid spread of the virus and the emergence of recent variations have underscores the urgent want for po-werful vaccination protocols.[1] Researchers have performed a pivotal function in investigating the protection, immunogenicity, and efficacy of Coronavirus Disease 2019 (COVID-19) vaccines.[3,7,9]

Systematic opinions and meta-analyses have found out that whilst mRNA vaccines exhibit higher effectiveness, they are related to a extra occurrence of destructive reactions than inactivated vaccines. [5] Additionally, vaccine acceptance ranges range notably based on geographical and socioeconomic factors. [2,6,8]

Proposed strategies to cope with these challenges encompass focused public fitness tasks to beautify vaccine adoption, such as tailor-made communique campaigns to address network worries and dispel incorrect information. [4] Booster doses have also been explored to sustain immunity stages, mainly amongst prone populations. [9]

The research examines the viability and efficacy of diverse COVID-19 vaccine formulations during heterogeneous populations on the equal time as delineating the factors influencing vaccine recognition. The findings advocate that mRNA vaccines monitor better efficacy, and inactivated vaccines may additionally additionally offer a more secure opportunity for precise demographic cohorts, specially humans with underlying fitness conditions. [7,10-12]

Methods and Procedures
Study Execution and Justification
The studies assessed the viability and efficacy of COVID-19 vaccines making use of an umbrella evaluate technique. This strategic preference aimed to amalgamate insights from a couple of systematic analyses and meta-reviews, facilitating a holistic comprehension of vaccine overall performance and protection metrics within heterogeneous cohorts.

Participant Selection Criteria
Inclusion Criteria
Systematic reviews or meta-analyses posted in peer-reviewed English journals investigating the efficacy and feasibility of COVID-19 vaccines were considered.

Exclusion Criteria
- Non-systematic value determinations concentrating totally on vaccine protection, redundant courses, and research devoid of empirical data had been unnoticed.

Demographic Attributes
Participants inside the covered fee determinations encompassed a severa array of age brackets, genders, and health statuses.

Research Objectives
The primary cause concerned consolidating evidence on the safety and effectiveness of severe Coronavirus Disease 2019 (COVID-19) vaccines in the route of severe demographics and health conditions.

Methodological Framework and Tools
The quest strategy entailed an exhaustive scrutiny of PubMed, Web of Science, and Scopus databases. The analytical arsenal comprised:

Reagents and Pharmaceuticals
Assorted vaccines were scrutinized, encompassing mRNA formulations (e.G., BNT162b2 with the resource of Pfizer/BioNTech and mRNA-1273 by manner of Moderna) and inactivated versions (e.G., CoronaVac with the aid of Sinovac). Dosages and control routes adhered to across the world sanctioned nomenclature delineated within the deliver research.

Findings and Outcomes
This in-depth exam delved into the efficacy and repercussions of diverse COVID-19 immunizations, scrutinizing consequences across distinct vaccine classifications by using drawing from 23 exhaustive systematic evaluations and meta-analyses.

1. Exploration of Literature Search Methodology
Initially, 993 articles surfaced via a methodical exploration. Following the removal of duplicates (n=20), the final 973 research underwent rigorous scrutiny based on their titles, abstracts, and complete texts, except 950 studies.
Upon meticulous evaluation of the eligibility of the ultimate 252 research, 229 have been disregarded because of inadequate empirical facts (n=224) and opportunity have a look at typologies (n=five). Ultimately, 23 articles aligned with the eligibility standards and have been assimilated into the contemporary research (Figure 1)

Figure 1: Diagram illustrating the retrieval process of the study

2. Attributes of the Encompassed Research:

These investigations were conducted across a varied spectrum of nations, including, but not limited to, Saudi Arabia, USA, Iran, China, Poland, Algeria, Italy, Georgia, Indonesia, Chile, Bangla, Bangladesh, Singap, Taiwan, Austral, Japan, Thailand, Korea, United Kingdom, Egypt, and Qatar (See Table 1).

Table 1: Attributes of the Encompassed Studies

I D	The first author	Type of review	Sources searched	Population	Purpose	Type of vaccine	Outcome
1	Slawomir M Janusze k [28]	System atic Review	Pubme d	Pregnan women	Exploring pregnant women's views on COVID-19 vaccination and the factors affecting their acceptance.	NR	Geographic and pandemic factors greatly impact vaccine acceptance, varying risks and threats from infection in Asian and South American countries.
2	Rinaldi [23]	System atic Review Meta analysis	PubMe d Scopus	Individu als with hematolo gic malignan cies	To evaluate the efficacy and safety of COVID-19 mRNA vaccines in individuals with hematologic malignancies.	AstraZe neca Pfizer-BioNTe ch Modern a vaccine s.	- The vaccine response was notably affected by the cancer type and treatment status. - Both individuals with hematologic malignancies and healthy controls demonstrated vaccine safety.
3	Mehrae en [8]	System atic Review	Scopus, PubMe d, Cochra ne	Unspecif ied	To perform an extensive analysis of adverse events linked to mRNA vaccines based on existing	Modern a	- Severe adverse reactions to COVID-19 vaccines are uncommon. - The advantages of vaccination against severe COVID-19 and mortality surpass the occasional rare adverse events.

						literature.
4	Shear [20]	Systematic Review	PubMed Web of Science	Individuals with solid tumor cancers	To determine the extent of COVID-19 vaccine side effects in individuals with solid tumors.	Pfizer-BioNTech, Moderna, AstraZeneca	- effects: fatigue, muscle pain, and headaches. - Majority of side effects were mild to moderate.
5	Tan [18]	Sryestematic Review	PubMed	Individuals with lupus nephritis	To assess the efficacy, efficiency, acceptability, and safety of COVID-19 vaccination in individuals with systemic lupus erythematosus	mRNA, viral vector, inacti-vated viral	Post-COVID-19 vaccination, cases of infection, severe flares, and adverse events were rare, but there was notable diversity in seropositivity and acceptance rates.
6	Teh, J. [19]	Saystematic Review and Meta-analysis	MEDLINE, EMBASE,and Cochrane	Individuals with hematologic malignancies who have received a minimum of one dose of COVID-19 vaccines.	To assess the immune response and safety of COVID-19 vaccines in individuals with hematologic malignancies.	Pfizer-BioNTech Moderna Vaxzevria	- Neutralizing antibodies post two doses varied from 57% to 60%, with cellular responses ranging between 40% and 75%. - The lowest seropositivity rate (51%) was noted in patients with chronic lymphocytic leukemia, whereas the highest (93%) was observed in those with acute leukemia.
7	Cheng , [17]	systematic review and meta-analysis	PubMed, Embase, Cochrane Library, and Web of Sci-ence	compassed four different COVID-19 vaccines: Matrix-M (NVX-CoV2373) Alum (BBV152) CpG-1018/Alum (SCB-2019) AS03 (CoVLP).	This study aimed to address the effectiveness of COVID-19 vaccines against variants of concern (VOC) of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).	NVX-CoV2373, CoVLP, SCB-2019, BBV152	Adjuvanted COVID-19 vaccines show varying efficacy against different variants, raising concerns about booster effectiveness against Omicron.
8	Fernán dez-García	systematic review	Multiple databas	women before or during	Assessing the effects of COVID-19	Receiving any COVID	COVID-19 vaccination in pregnant women is highly effective, improving

		[15]	and meta-analysis	es were queried for COVID-19 studies in pregnant women from December 2019 to January 2023.	pregnancy	vaccines on pregnant or pre-pregnant women for infection, pregnancy, offspring, and side effects.	-19 vaccine.	outcomes without major safety concerns, though impacted by changing recommendations and virus variants.
9	Li [17]	systematic review and meta-analysis	PubMed ,Web of Science	CKD patient undergoing dialysis.	The effectiveness and safety of the COVID-19 vaccine on the immune response in CKD patients undergoing dialysis.	BNT162B2, mRNA-1273, ChAdOx1-nCoV-19	Vaccination in CKD patients on dialysis is effective in reducing COVID-19 incidence with few adverse events	
10	Rubin M [13]	Systematic Review and Meta-Analysis	Scopus, Web of Science	Allogeneic Hematopoietic Stem Cell Recipients	assessed the efficacy of a third SARS-CoV-2 vaccine dose in allo-HCT recipients.	Pfizer x 3 Moderna x 3	A 74% humoral response rate was observed with three SARS-CoV-2 vaccine doses in allo HSCT recipients, indicating the need for additional doses for non-responders pending larger studies.	
11	Tamb [32]	systema review and meta-analysis	PubMed, Cochrane Library, MEDLINE, and Embase were searched.	Patients undergoing renal replacement therapy.	We conducted a meta-analysis on triple-dose COVID-19 vaccination in RRT patients.	mRNA vaccines	Triple-dose COVID-19 vaccination in RRT patients reduces immunogenicity, especially in KTRs	
12	Santimano [12]	Systematic Review and Meta-Analysis	PubMed, Scopus, and EMBASE databases	Pregnant women	This review aimed to offer a detailed overview of vaccine efficacy in pregnant women	Pfizer/ BioNTech and Moderna	COVID-19 mRNA vaccine had similar side effects in pregnant and non-pregnant women, reducing maternal and fetal risks.	
13	Yang [16]	Systematic	PubMed	Adults greater	To evaluate the efficacy of	Pfizer-BioNTe	Vaccinating the elderly with SARS-CoV-2	

		Review and Meta-analysis	Web of Science	than 60 years of age	COVID-19 vaccines and their impact on breakthrough infections, hospitalizations, and mortality in the elderly demographic.	ch Moderna	vaccines prevents infections, hospitalizations, and deaths, with increased efficacy from more doses.
14	Sandoval [21]	Systematic Review	Web of Science, Scopus,	People over 18 years old	Exploring the effectiveness, immune response, and safety of emerging SARS-CoV-2 vaccination technologies for individuals 18 and above.	Moderna Pfizer-BioNTech AstraZeneca	Various COVID-19 vaccines reduce hospitalization and death in adults, protect against symptomatic illness, show strong efficacy and safety, but declining immunity and new variants may lessen infection resistance.
15	Sadeghi, [22]	Systematic Review and Meta-analysis	Systematic Review and Meta-analysis	Children and adolescents.	Gathering data on the efficacy, safety, and immune response of COVID-19 vaccines in individuals aged 2 to 21 years to provide guidance to healthcare providers and families.	mRNA, Viral Vector, Inactivated Virus, Recombinant Adenovirus Type-5 (Ad5), Plasmid DNA	Recent review confirms vaccine safety for children and adolescents, with occasional issues like myocarditis addressed. Vaccination for ages 2-21 is crucial in pandemic control, supported by high efficacy rates.
16	Chiara Primieri [33]	Systematic Review	PubMed	Italian population.	Examine the factors influencing COVID-19 vaccination acceptance or hesitancy among the Italian population.	NON	These results are vital for designing targeted strategies to combat COVID-19 vaccine hesitancy in Italy.
17	Salah Eddine Oussama Kacimi [27]	Systematic Review	From the beginning of Medline to May 16, 2021.	Not specified.	Factors influencing the acceptance of the COVID-19 vaccine among the Algerian population.	NON	The significantly low rates of vaccine uptake among the Algerian population likely account for the slow increase in the vaccination rate in the country.
18	Yu Jing Fan [30]	Systematic Review and	PubMed and	Not Specified	Assess the safety and effectiveness of COVID-19	Moderna Oxford-AstraZe	The findings suggest that the optimal prevention of SARS-CoV-2 infection is achieved with two doses of

		Meta-Analysis	EMBASE		vaccines released in 2019 based on vaccine type and the severity of SARS-CoV-2 infection.	neca putnik V Pfizer-BioNTech	mRNA vaccines.
19	Omid Dadras [31]	Systematic Review	PubMed Web of Science	Not Speci-fied	adverse events reported for inactivated vaccines and Novavax	AstraZeneca & Pfizer	safe with milder side effects and fewer severe adverse events.
20	Cangca [29]	Systematic Review	Web of Science PubMed Google Scholar	People who were overweight or obese	Evaluate the correlation between overweight/obesity and the effectiveness and safety of COVID-19 vaccination by consolidating the existing evidence.	Pfizer AstraZeneca Moderna Sinovac	Although the effectiveness of the COVID-19 vaccine may be somewhat reduced in individuals who are overweight or obese, it remains crucial for obese individuals to receive the vaccine as it can still offer some level of protection.
21	Meng LV [34]	Systematic Review	PubMed Web of Science WHO	Children or adolescents (aged under 18 years)	To assess the safety, immune response, and protective effectiveness of COVID-19 vaccines in children and adolescents.	CoronaVac BNT162b2	Two COVID-19 vaccines show promising protective effects in children and adolescents; however, vigilance is essential to monitor potential adverse effects following administration.
22	Rawal, [24]	Systematic Review	PubMed, Web of Science	Pregnant individuals in the United States.	Evaluate COVID-19 vaccination in pregnant individuals in the US.	Moderna Pfizer	Studies confirm COVID-19 vaccine safety for pregnant individuals and newborns.
23	Sharif [7]	Systematic Review Metaanalysis	PubMed Web of Science Scopus	Not Specified	Analyze literature to evaluate COVID-19 vaccine effectiveness, immune response, and safety.	Pfizer oxford AstraZeneca	Adenovirus vaccines 73% effective, mRNA 85%. Over 90% develop antibodies post-vaccination. Common side effects vary. Moderate to high protection for adults; limited data for under 16, especially against variants.

Outcomes Summary

Adenovirus vaccines are 73% effective, mRNA 85%. Over 90% develop antibodies post-vaccination. Common side effects vary. Moderate to high protection for adults; limited data for under 16, especially against variants.

Table 1: Attributes of the Encompassed Studies

The research has focused on a variety of COVID-19 vaccine types, including the mRNA vaccines from Pfizer and Moderna, the viral vector vaccines from Johnson & Johnson and Oxford, as well as inactivated virus vaccines like those from Sinovac and Sinopharm. [1]

These vaccines have been studied in diverse populations, including people with specific medical conditions such as inflammatory bowel disease, cancer, kidney disease, and autoimmune disorders, as well as different age groups like children, the elderly, and pregnant women. [20]

From what the studies have proven, the COVID-19 vaccines normally seem to be powerful at protecting humans and triggering an excellent immune reaction, especially in adults. [21] Certain vaccines like Sinovac, Sinopharm, Bharat Biotech, and Novavax seem to have milder side effects than others. [31] Both the adenovirus-based total vaccines and the mRNA vaccines have verified the ability to generate neutralizing antibodies effectively. [11] The statistics additionally show that these vaccines are The research has proven that those COVID-19 vaccines are normally safe and effective even for humans dealing with some quite serious fitness demanding situations. [12] Things like organ transplants, cancer, and autoimmune problems can definitely take a toll at the body and make you greater prone. However, the statistics indicate that vaccines are preserving up nicely for oldsters in those medical situations.

That's reassuring, you recognize? not simply shielding the common wholesome grownup; they're offering that same shield of protection for individuals who want it. For folks going through organ transplant, cancer treatment, the vaccine can Protect them as well

the vaccine acceptance depending on the geographic region. [25, 27] The side effects are typically mild to moderate, . [30] The research suggests pregnant women and young people don't seem to have major safety concerns with these vaccines. [28] However, it's still important that they continue closely monitoring for any adverse effects, especially potential differences based on gender and dosing.

CONCLUSION

The findings demonstrate the effectiveness and safety of Coronavirus Disease 2019 (COVID-19) vaccines, especially mRNA formulations, across diverse populations, including those with specific medical conditions. These insights are pivotal for shaping vaccination strategies and tackling public health challenges. [34]

DISCUSSION

In this study, we evaluated the feasibility and effectiveness of COVID-19 vaccines, comparing our findings with those of preceding studies. Our analysis suggests that COVID-19 vaccines, specifically mRNA variants, exhibit high efficacy and generally desirable protection profiles across numerous populations, including those with specific health situations.

Comparing our findings with those of different researchers reveals numerous noteworthy variations. For example, while our records spotlight that mRNA vaccines like Pfizer and Moderna are related to a higher occurrence of destructive events, different research can also record distinctive protection profiles, particularly for inactivated vaccines like Sinovac and Sinopharm, which generally tend to expose fewer damaging reactions.

preceding research has recommended that vaccine efficacy may vary drastically among exclusive demographic organizations.

Our findings guide this belief, particularly about people with obesity, who appear to have a barely decreased immune response to mRNA vaccines.

These variations may be due to underlying health conditions that affect the immune system to respond effectively to vaccination.

The determined examination styles endorse a complex interplay between vaccine Type, people's fitness, and demographic factors.

The patterns underscore the significance of monitoring and studies,especially when new gens come out.

Our consequences align with the broader literature, indicating that vaccines are effective, but their effect can vary depending on populace characteristics and fitness situations.

Study Findings

The investigation efficaciously assessed the viability and efficacy of various COVID-19 vaccines, showcasing their standard safety and effectiveness among varied populations, such as those with underlying health complexities. The observer finished its goals by amalgamating statistics from numerous systematic reviews and meta-analyses, losing mild at the disparate protection profiles and efficacy stages of awesome vaccine classes like mRNA, inactivated, and protein subunit vaccines.

Nonetheless, the take a look at unveiled sure constraints, emphasizing the necessity for prolonged protection statistics regarding specific fitness conditions together with diabetes and high blood pressure. Subsequent studies endeavors must prioritize these regions to bridge the present knowledge lacunae.

Looking into the future, this area stands to get geared up for extremely good development. The discoveries may additionally want to lay the premise for precise vaccination techniques tailored to tremendous demographic segments and scientific scenarios, augmenting public health responses to Coronavirus Disease 2019 (COVID-19) and analogous health crises. These studies may also want to assist in broadening better booster shot strategies tailored to character wishes. That way, we will make sure the vaccines pack a stronger punch for each person, regardless of their unique circumstances.

The key is finding ways to reinforce immune responses that work for the man or woman. This is not a one-size-suits-all method; however, personalized answers reinforce safety across the board.

About enhancing the effectiveness of vaccines to offer an additional degree of safety towards this virus for absolutely everyone.

This analysis reveals a clear hypothesis: incorporating genetic and social factors should improve the effectiveness of vaccines in different population groups. Although this idea holds promise, it is still theoretical and needs to be carefully validated through scientific experiments to confirm its validity. As research progresses, it is essential to continue exploring the relationship between vaccine response and the characteristics of affected population groups to ensure that vaccinations are effective and equitable.

REFERENCES

1. Mehraeen, E., et al. (2022). Vaccines for COVID-19: A systematic review of feasibility and effectiveness. Infectious Disorders Drug Targets, 22(2), E230921196758.
2. Seyedalinaghi, S., et al. (2022). COVID-19 mortality in patients with immunodeficiency and its predictors: A systematic review. 27(1), 195.
3. Collier, A.-R. Y., et al. (2021). Differential kinetics of immune responses elicited by COVID-19 vaccines. New England Journal of Medicine, 385(21), 2010-2012.
4. Shreyas Madhav, A., et al. (2022). Application of artificial intelligence to enhance collection of e-waste: A potential solution for household WEEE collection and segregation in India. Waste Management & Research, 40(7), 1047-1053.
5. Pormohammad, A., et al. (2021). Efficacy and safety of COVID-19 vaccines: A systematic review and meta-analysis of randomized clinical trials. Vaccines, 9(5), 467.
6. Larijani, M. S., et al. (2022). Characterization of long COVID-19 manifestations and its associated factors: A prospective cohort study from Iran. Microbial Pathogenesis, 169, 105618.
7. Sharif, N., et al. (2021). Efficacy, immunogenicity, and safety of COVID-19 vaccines: A systematic review and meta-analysis. Frontiers in Immunology, 12, 4149.
8. Mehraeen, E., et al. (2022). COVID-19 in pediatrics: A systematic review of current knowledge and practice. Infectious Disorders Drug Targets, 22(5), 47-57.
9. Garcia-Beltran, W. F., et al. (2022). mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell, 185(3), 457-466.E4.
10. Logunov, D. Y., et al. (2020). Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. The Lancet, 396(10255), 887-897.
11. Ramasamy, M. N., et al. (2020). Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. The Lancet, 396(10267), 1979-1993.
12. Santimano, A. J., Al-Zoubi, R. M., Al-Qudimat, A. R., Al Darwish, M. B., Ojha, L. K., Rejeb, M. A., et al. (2024). Efficacy and clinical outcomes of mRNA COVID-19 vaccine in pregnancy: A systematic review and meta-analysis. Intervirology, 67(1), 40-54.
13. Rubin, M., Suelzer, E., Ulschmid, C., Thapa, B., Szabo, A., & Abid, M. B. (2024). Efficacy of SARS-CoV-2 vaccine doses in allogeneic hemopoietic stem cell recipients: A systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention: APJCP, 25(2), 393.
14. Li, K., Xia, Y., Ye, H., Sun, X., Shi, B., & Wu, J. (2024). Effectiveness and safety of immune response to SARS-CoV-2 vaccine in patients with chronic kidney disease and dialysis: A systematic review and meta-analysis. Biomedical Reports, 20(5), 1-10.
    Fernández-García, S., Del Campo-Albendea, L., Sambamoorthi, D., Sheikh, J., Lau, K., Osei-Lah, N., et al. (2024). Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: A systematic review and meta-analysis. BMJ Global Health, 9(4), e014247.
15. Yang, X. H., Bao, W. J., Zhang, H., Fu, S. K., Jin, H. M. (2023). The efficacy of SARS-CoV-2 vaccination in the elderly: A systematic review and meta-analysis. Journal of General Internal Medicine, 1-9.
16. Cheng M-Q, Weng Z-Y, Li R, Song G. Efficacy of adjuvant-associated COVID-19 vaccines against SARS-CoV-2 variants of concern in randomized controlled trials: a systematic review and meta-analysis. Medicine. 2024;103(7):e35201.

17. Tan, S. Y. S., Yee, A. M., Sim, J. J. L., & Lim, C. C. (2023). COVID-19 vaccination in systemic lupus erythematosus: A systematic review of its effectiveness, immunogenicity, flares and acceptance. Rheumatology, 62(5), 1757-1772.

18. Teh, J. S., Coussement, J., Neoh, Z. C., Spelman, T., Lazarakis, S., Slavin, M. A., & et al. (2022). Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: A systematic review and meta-analysis. Blood Advances, 6(7), 2014-2034.

19. Shear, S., Shams, K., Weisberg, J., Hamidi, N., & Scott, S. (2023). COVID-19 vaccination safety profiles in patients with solid tumour cancers: A systematic review. Clinical Oncology.

20. Sandoval C, Guerrero D, Muñoz J, Godoy K, Souza-Mello V, Farías J. Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review. Expert Review of Vaccines. 2023;22(1):35-53.

21. Sadeghi, S., Kalantari, Y., Shokri, S., Fallahpour, M., Nafissi, N., Goodarzi, A., et al. (2022). Immunologic response, efficacy, and safety of vaccines against COVID-19 infection in healthy and immunosuppressed children and adolescents aged 2-21 years old: A systematic review and meta-analysis. Journal of Clinical Virology, 153, 105196.

22. Rinaldi, I., Pratama, S., Wiyono, L., Tandaju Jr, R., Wardhana, I. L., & Winston, K. (2022). Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis. *Frontiers in Oncology*, 12, 951215.

23. Rawal, S., Tackett, R. L., Stone, R. H., Young, H. N. (2022). COVID-19 vaccination among pregnant people in the United States: A systematic review. American Journal of Obstetrics & Gynecology MFM, 4(4), 100616.

24. Primieri C, Bietta C, Giacchetta I, Chiavarini M, De Waure C. Determinants of COVID-19 vaccination acceptance or hesitancy in Italy: an overview of the current evidence. Annali dell'Istituto Superiore di Sanità. 2023;59(1):10-25.

25. Lv, M., Luo, X., Shen, Q., Lei, R., Liu, X., Liu, E., et al. (2021). Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: A systematic review. Vaccines, 9(10), 1102.

26. Kacimi SEO, Klouche-Djedid SN, Riffi O, Belaouni HA, Yasmin F, Essar MY, et al. Determinants of COVID-19 vaccine engagement in Algeria: a population-based study with systematic review of studies from Arab countries of the MENA region. Frontiers in Public Health. 2022;10:843449.

27. Januszek, S. M., Faryniak-Zuzak, A., Barnaś, E., Łoziński, T., Góra, T., Siwiec, N., et al. (2021). The approach of pregnant women to vaccination based on a COVID-19 systematic review. Medicina, 57(9), 977.

28. Harada, R., Oyama, T., Fujimoto, K., Shimizu, T., Ozawa, M., Amar, J. S., et al. (2023). Trash detection algorithm suitable for mobile robots using improved YOLO. *Journal of Advanced Computational Intelligence and Intelligent Informatics*, 27(4), 622–631.

29. Fan, Y.-J., Chan, K.-H., & Hung, I. F.-N. (2021). Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of different vaccines at phase 3. *Vaccines*, 9(9), 989.

30. Dadras O, Mehraen E, Karimi A, Tantuoyir MM, Afzalian A, Nazarian N, et al. Safety and adverse events related to inactivated COVID-19 vaccines and Novavax; a systematic review. Archives of Academic Emergency Medicine. 2022;10(1).

31. Tamb BMMAR, Chana KW, Chi IFNHS, Chana WTTM, & Yapa DY-H. (2024). Immunogenicity and Safety of the Three-Dose COVID-19 Vaccine Regimen in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis. Mortality, 1(4).

32. Primieri C, Bietta C, Giacchetta I, Chiavarini M, & De Waure C. Determinants of COVID-19 vaccination acceptance or hesitancy in Italy: An overview of the current evidence.

33. Lv M, Luo X, Shen Q, Lei R, Liu X, Liu E, et al. (2021). Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: A systematic review. *Vaccines*, 9(10), 1102.